In the area of Gram-positive infections, methicillin-resistant Staph (MRSA) and vancomycin-resistant Enterococcus (VRE) pose a major threat to patients in hospitals and community health facilities by producing skin, wound, and systemic infections that cannot always be safely treated by currently available therapies. Beyond these current threats, Gram-negative bacteria such as Pseudomonas aeruginosa and Acinetobacter baumanii are an emerging threat, with some patients in special circumstances (wounded soldiers, Cystic Fibrosis sufferers) already affected by these pan-resistant pathogens. The need for new antibacterials has not been more urgent in decades.
DeNovaMed is rising to that challenge, aiming to bring to market new antibacterials with entirely new mechanisms of action that will help people suffering from resistant infections.
Goldbloom Research Pavillion
5980 University Ave
PO Box 9700
Halifax, Nova Scotia